BIIB34:BVMF
Biogen Inc BDR
R$ २३०.१०
०.००%
(०.००) 1D
नोभेम्बर ५, २२:३२:१८ GMT-३ · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Mkt. cap
३६.०६ अरब
Avg. vol.
९.००
Volume
०.००
52-wk high
R$ २३०.१०
52-wk low
R$ १३७.९०
Shares outstanding
१४.७८ करोड
No. of employees
८ हजार
Mkt. cap
३६.०६ अरब
Avg. vol.
९.००
Volume
०.००
52-wk high
R$ २३०.१०
52-wk low
R$ १३७.९०
Shares outstanding
१४.७८ करोड
No. of employees
८ हजार
News stories
From web sources and news partners
MarketWatch
·
९ घण्टा पहिले
Biogen Inc. stock underperforms Thursday when compared to competitors
Yahoo Finance
·
१५ घण्टा पहिले
Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone)
Yahoo Finance Singapore
·
२२ घण्टा पहिले
Is Alzheimer’s Data Altering The Investment Case For Biogen (BIIB)?
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees७.५ हजार
Founded१९७८
Headquartersक्याम्ब्रिज, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Websitebiogen.com